Efficacy of ThermoProfen in Patients With Mild to Moderate Pain Associated With Osteoarthritis of the Knee

NCT ID: NCT00488267

Last Updated: 2012-05-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

679 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-06-30

Study Completion Date

2008-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

ThermoProfen is a transdermal ketoprofen patch that is integrated with a long-lasting CHADD (Controlled Heat-Assisted Drug Delivery) unit for the treatment of chronic pain associated with osteoarthritis. This study will evaluate ThermoProfen for the treatment of mild to moderate pain associated with osteoarthritis of the knee in adults.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of the study is to compare the efficacy of ThermoProfen™ against two other experimental treatments.

The treatment may be ThermoProfen (Matrix Transdermal Ketoprofen Patch) or a patch that may or may not include ketoprofen and that may or may not provide heat.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Thermoprofen

ThermoProfen™ (ketoprofen matrix/Controlled Heat Assisted Drug Delivery \[CHADD™\] patch)

Group Type EXPERIMENTAL

ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System)

Intervention Type DRUG

Transdermal patch applied to the knee for 12 hours daily.

Placebo Matrix

Placebo matrix with CHADD patch.

Group Type PLACEBO_COMPARATOR

Placebo Matrix/CHADD Patch

Intervention Type DRUG

Transdermal patch applied to the knee for 12 hours daily.

Ketoprofen matrix/placebo CHADD

Ketoprofen matrix with placebo CHADD patch (no heat)

Group Type PLACEBO_COMPARATOR

Ketoprofen matrix/placebo CHADD Patch

Intervention Type DRUG

Transdermal knee applied to the knee for 12 hours daily.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System)

Transdermal patch applied to the knee for 12 hours daily.

Intervention Type DRUG

Placebo Matrix/CHADD Patch

Transdermal patch applied to the knee for 12 hours daily.

Intervention Type DRUG

Ketoprofen matrix/placebo CHADD Patch

Transdermal knee applied to the knee for 12 hours daily.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Matrix Transdermal Ketoprofen CHADD System Placebo patch with heating system ketoprofen matrix with no heat

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient is 18 through 75 years of age
* Patient has radiographic evidence of osteoarthritis of the target knee obtained within the past year.

Exclusion Criteria

* Patient has a known allergy to nonsteroidal anti-inflammatory drugs (NSAIDs, including aspirin).
* Patient has asthma that has been induced or made worse by the use of aspirin or NSAIDs.
* Patient has a relevant history of serious gastrointestinal disease.
* Patient, if female, is pregnant or breastfeeding or is of childbearing potential and not practicing adequate birth control.
* Patient is taking warfarin, heparin, or low molecular weight heparin.
* Patient has received oral, intramuscular, intravenous, intra-articular, or soft-tissue administration of steroids within 1 month of study enrollment (or within 2 months, if in the target joint).
* Patient has received intra-articular visco-supplementation (in target joint) within 6 months of study enrollment.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

ZARS Pharma Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Monitor

Role: STUDY_DIRECTOR

ZARS Pharma

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Peoria, Arizona, United States

Site Status

Anaheim, California, United States

Site Status

Buena Park, California, United States

Site Status

San Diego, California, United States

Site Status

Westlake Village, California, United States

Site Status

Hamden, Connecticut, United States

Site Status

Milford, Connecticut, United States

Site Status

Clearwater, Florida, United States

Site Status

Jupiter, Florida, United States

Site Status

Pembroke Pines, Florida, United States

Site Status

South Miami, Florida, United States

Site Status

Tampa, Florida, United States

Site Status

Boise, Idaho, United States

Site Status

Springfield, Illinois, United States

Site Status

Evansville, Indiana, United States

Site Status

Overland Park, Kansas, United States

Site Status

Baltimore, Maryland, United States

Site Status

Wheaton, Maryland, United States

Site Status

Lansing, Michigan, United States

Site Status

Kansas City, Missouri, United States

Site Status

Mercerville, New Jersey, United States

Site Status

Greensboro, North Carolina, United States

Site Status

Raleigh, North Carolina, United States

Site Status

Lake Oswego, Oregon, United States

Site Status

Portland, Oregon, United States

Site Status

Duncansville, Pennsylvania, United States

Site Status

Erie, Pennsylvania, United States

Site Status

Mechanicsburg, Pennsylvania, United States

Site Status

Anderson, South Carolina, United States

Site Status

Myrtle Beach, South Carolina, United States

Site Status

Nashville, Tennessee, United States

Site Status

Houston, Texas, United States

Site Status

San Antonio, Texas, United States

Site Status

Salt Lake City, Utah, United States

Site Status

Spokane, Washington, United States

Site Status

Tacoma, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ZMK-301

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Toward Better Outcomes in Osteoarthritis
NCT00000425 COMPLETED PHASE3